循环淋巴细胞耗竭表型逆转作为霍奇金淋巴瘤一线抗PD1治疗的免疫相关标志
该研究基于NIVAHL试验(NCT03004833)81例霍奇金淋巴瘤患者序贯样本,采用多色流式、FluoroSpot和NanoString分析抗PD1一线治疗中循环淋巴细胞表型及系统效应。患者基线CD4 T细胞比例降低、效应记忆T细胞比例升高、激活标志物表达增高,且16种共抑制分子中10种在T细胞上表达高于实体瘤。治疗中耗竭T细胞表型持续下降,42.3%患者对≥1种肿瘤相关抗原产生T细胞应答,且该应答在早期疗效优异者中更常见。
要点
- 霍奇金淋巴瘤患者基线循环T细胞呈耗竭表型,共抑制分子表达高于实体瘤。
- 抗PD1一线治疗中耗竭表型持续逆转,提示系统免疫恢复。
- 42.3%患者出现肿瘤相关抗原特异性T细胞应答,与早期优异疗效相关。
核心结论
- 霍奇金淋巴瘤患者基线循环淋巴细胞呈耗竭表型,抗PD1一线治疗中该表型快速逆转。
- 针对共享肿瘤相关抗原的IFN-γ应答常见,且与早期优异疗效相关,可能反映T细胞介导的细胞毒性。
研究设计与样本
- 基于NIVAHL试验(NCT03004833)的81例霍奇金淋巴瘤患者序贯样本研究。
- 采用多色流式细胞术、FluoroSpot和NanoString分析,并与健康对照比较。
主要发现
- 基线时霍奇金淋巴瘤患者CD4 T细胞比例降低,效应记忆T细胞比例升高,激活标志物表达增高。
- 16种共抑制分子中10种(如PD1、LAG3、Tim3)在霍奇金淋巴瘤T细胞上表达高于实体瘤。
- 抗PD1治疗中耗竭T细胞表型持续下降。
- 42.3%患者FluoroSpot检测到针对5种肿瘤相关抗原中≥1种的T细胞应答。
- 这些应答在早期对PD1治疗反应优异的患者样本中更常见。
临床怎么用
- 循环耗竭T细胞表型逆转及肿瘤相关抗原特异性IFN-γ应答可作为抗PD1治疗免疫监测的候选指标。
- 肿瘤相关抗原特异性T细胞应答可能为霍奇金淋巴瘤细胞治疗提供资源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While classical Hodgkin lymphoma (HL) is highly susceptible to anti-programmed death protein 1 (PD1) antibodies, the exact modes of action remain controversial. To elucidate the circulating lymphocyte phenotype and systemic effects during anti-PD1 1st-line HL treatment we applied multicolor flow cytometry, FluoroSpot and NanoString to sequential samples of 81 HL patients from the NIVAHL trial (NCT03004833) compared to healthy controls. HL patients showed a decreased CD4 T-cell fraction, a higher percentage of effector-memory T cells and higher expression of activation markers at baseline. Strikingly, and in contrast to solid cancers, expression for 10 out of 16 analyzed co-inhibitory molecules on T cells (e.g., PD1, LAG3, Tim3) was higher in HL. Overall, we observed a sustained decrease of the exhausted T-cell phenotype during anti-PD1 treatment. FluoroSpot of 42.3% of patients revealed T-cell responses against ≥1 of five analyzed tumor-associated antigens. Importantly, these responses were more frequently observed in samples from patients with early excellent response to anti-PD1 therapy. In summary, an initially exhausted lymphocyte phenotype rapidly reverted during anti-PD1 1st-line treatment. The frequently observed IFN-y responses against shared tumor-associated antigens indicate T-cell-mediated cytotoxicity and could represent an important resource for immune monitoring and cellular therapy of HL.
引用
- Garcia-Marquez MA, Thelen M, Reinke S, et al. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma. Leukemia. 2021. PMID: 34584203. doi:10.1038/s41375-021-01421-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。